The PARADIGM-HF, phase III, randomized, double-blind trial, which compared to an ACE inhibitor, enalapril in HF patients with reduced ejection fraction, resulted in a reduced risk of death and of rehospitalization for HF, together with reduced circulating levels of NT-proBNP in 2014 [27]. Here, NPPB is linked to hydrops fetalis.